Conditions: Alzheimer's Disease
Keywords: Alzheimer's disease cholinesterase inhibitor rivastigmine
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 228

Brief summary:
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm\^2 in patients with probable Alzheimer's Disease (Mini-Mental State Examination 10-26) in the community setting

Detailed description:

Arms:

Interventions: intervention 1: Rivastigmine transdermal patch
Intervention descriptions: intervention 1: The study treatment was delivered as a patch sizes 5 and 10 cm\^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\^2.

Protocol document: